Home » Topics » BioWorld Science

BioWorld Science
RSS

Multidrug resistance modifiers from Vertex

July 12, 1996

Interim phase I/IIa results for Genta's G-3139 as non-Hodgkin's lymphoma agent

July 12, 1996

Canji issued two patents for p53 gene therapy for cancer

July 12, 1996

Arizona Board of Regents reports antitumor pentapeptides

July 12, 1996

Potent tyrosine kinase inhibitors derived from PD-089828

July 12, 1996

Protein farnesyltransferase inhibitor in Warner-Lambert's compound library

July 12, 1996

PD-158780: A potent and selective EGF tyrosine kinase inhibitor

July 12, 1996

Protein tyrosine kinase inhibitors from Warner-Lambert

July 12, 1996

Multikine enters Canadian phase I/II trial

July 12, 1996

Arimidex approved for Austrian, German and Italian markets

July 12, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 9, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome
BioWorld Science
The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...